Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.
SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has tr...
Saved in:
Main Authors: | Ernesto Bermúdez-Abreut, Talia Fundora-Barrios, Diana Rosa Hernández Fernández, Enrique Noa Romero, Anitza Fraga-Quintero, Ana V Casadesús Pazos, Briandy Fernández-Marrero, Claudia A Plasencia Iglesias, Marilyn Clavel Pérez, Katya Sosa Aguiar, Belinda Sánchez-Ramírez, Tays Hernández |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0312402 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Genetic determinants of COVID-19 severity and mortality: ACE1 Alu 287 bp polymorphism and ACE1, ACE2, TMPRSS2 expression in hospitalized patients
by: João Locke Ferreira de Araújo, et al.
Published: (2025-01-01) -
The ACE2/Apelin Signaling, MicroRNAs, and Hypertension
by: Lai-Jiang Chen, et al.
Published: (2015-01-01) -
The Protective Potential Role of ACE2 against COVID-19
by: Fereshteh Golab, et al.
Published: (2023-01-01) -
Sleep: An unplayed ace in research and treatment of youth with ACEs
by: Sarah L.H. Kamhout, et al.
Published: (2025-04-01) -
Droplet microfluidic screening to engineer angiotensin-converting enzyme 2 (ACE2) catalytic activity
by: Evelyn F Okal, et al.
Published: (2025-02-01)